WallStSmart

CryoCell International Inc (CCEL)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 15923% more annual revenue ($5.06B vs $31.57M). ENSG leads profitability with a 6.8% profit margin vs -7.7%. CCEL appears more attractively valued with a PEG of 1.34. ENSG earns a higher WallStSmart Score of 57/100 (C).

CCEL

Hold

37

out of 100

Grade: F

Growth: 4.7Profit: 4.5Value: 6.7Quality: 5.0

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CCEL.

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL1 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

Areas to Watch

CCEL4 concerns · Avg: 2.0/10
Market CapQuality
$25.13M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-2.3%2/10

Revenue declined 2.3%

EPS GrowthGrowth
-30.8%2/10

Earnings declined 30.8%

Profit MarginProfitability
-7.7%1/10

Currently unprofitable

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bear Case : CCEL

The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while ENSG is a growth play — different risk/reward profiles.

ENSG carries more volatility with a beta of 0.80 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (57/100 vs 37/100) and 20.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?